Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor

• US 5,612,201 A
• Filed: 09/01/1994
• Issued: 03/18/1997
• Est. Priority Date: 05/23/1991
• Status: Expired due to Term

• Current Assignee: Ludwig Institute for Cancer Research, Ltd.
• Original Assignee: Ludwig Institute for Cancer Research, Ltd.
• Inventors: De Plaen, Etienne, Chomez, Patrick, Lethe, Bernard, De Smet, Charles, Boon-Falleur, Thierry, Szikora, Jean-Pierre
• Primary Examiner(s): Zitomer, Stephanie W.
• Assistant Examiner(s): REES, DIANE
• Application Number:
  US08/299,849
• Time in Patent Office: 929 Days
• Field of Search: 435/6, 435/91.2, 536/23.1, 536/24.3-24.33
• US Class Current: 435/91.2
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: C07K 14/4748 Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
• CPC Class Codes: C07K 16/30 from tumour cells
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: C12Q 2600/172 Haplotypes

Abstract

The invention relates to nucleic acid molecules which are useful in determining expression of the family of molecules known as the MAGE tumor rejection antigen precursors. These nucleic acid are molecules useful as diagnostic aids for determining whether or not an individual has cancer. Methods using these molecules are also described.

Claims

1. Isolated nucleic acid molecule selected from the group consisting of:

SEQ ID NO;

29, SEQ ID NO;

30, SEQ ID NO;

31, SEQ ID NO;

32, SEQ ID NO;

33, SEQ ID NO;

34, SEQ ID NO;

35, SEQ ID NO;

36, SEQ ID NO;

37, SEQ ID NO;

38, SEQ ID NO;

39, SEQ ID NO;

40, SEQ ID NO;

41, SEQ ID NO;

42, SEQ ID NO;

43, SEQ ID NO;

44, SEQ ID NO;

45, and SEQ ID NO;

46.

2. Kit useful in determining expression of a MAGE gene, said kit comprising at least one pair of primers selected from the group consisting:

(b) SEQ ID NO;

29 and SEQ ID NO;

30

(c) SEQ ID NO;

31 and SEQ ID NO;

32

(d) SEQ ID NO;

33 and SEQ ID NO;

34

(e) SEQ ID NO;

35 and SEQ ID NO;

36

(f) SEQ ID NO;

37 and SEQ ID NO;

38

(g) SEQ ID NO;

39 and SEQ ID NO;

40

(h) SEQ ID NO;

41 and SEQ ID NO;

42

(i) SEQ ID NO;

43 and SEQ ID NO;

44 and

(j) SEQ ID NO;

45 and SEQ ID NO;

46.

3. Method for determining expression of a MAGE gene of interest, comprising contacting a nucleic acid containing sample with at least one pair of primers selected from the group consisting:

(b) SEQ ID NO;

29 and SEQ ID NO;

30

(c) SEQ ID NO;

31 and SEQ ID NO;

32

(d) SEQ ID NO;

33 and SEQ ID NO;

34

(e) SEQ ID NO;

35 and SEQ ID NO;

36

(f) SEQ ID NO;

37 and SEQ ID NO;

38

(g) SEQ ID NO;

39 and SEQ ID NO;

40

(h) SEQ ID NO;

41 and SEQ ID NO;

42

(i) SEQ ID NO;

43 and SEQ ID NO;

44 and

(j) SEQ ID NO;

45 and SEQ ID NO;

46, subjecting said nucleic acid containing sample and pair of primers to a reverse transcriptase-polymerase chain reaction, and determining any amplification product as a determination of expression of said MAGE gene.